Emergency Institute for Cardiovascular Diseases and Transplantation

Târgu-Mureş, Romania

Emergency Institute for Cardiovascular Diseases and Transplantation

Târgu-Mureş, Romania

Time filter

Source Type

Fumagalli S.,University of Florence | Chen J.,Haukeland University Hospital | Chen J.,University of Bergen | Dobreanu D.,Victor Babes University of Medicine and Pharmacy Timisoara | And 4 more authors.
Europace | Year: 2016

Management of patients with cardiac arrhythmias is increasingly complex because of continuous technological advance and multifaceted clinical conditions associated with ageing of the population, the presence of co-morbidities and the need for polypharmacy. The aim of this European Heart Rhythm Association Scientific Initiatives Committee survey was to provide an insight into the role of the Arrhythmia Team, an integrated, multidisciplinary approach to management of patients with cardiac arrhythmias. Forty-eight centres from 18 European countries replied to the Web-based questionnaire. The presence of an Arrhythmia Team was reported by 44% of the respondents, whereas 17% were not familiar with this term. Apart from the electrophysiologist, health professionals who should belong to such teams, according to the majority of the respondents, include a clinical cardiologist, a nurse, a cardiac surgeon, a heart failure specialist, a geneticist, and a geriatrician. Its main activity should be dedicated to the management of patients with complex clinical conditions or refractory or inherited forms of arrhythmias. When present, the Arrhythmia Team was considered helpful by 95% of respondents; the majority of centres (79%) agreed that it should be implemented. The Arrhythmia Team seems to be connected to important expectations in the management of cardiac arrhythmias. The efficacy of such an integrated and multidisciplinary approach should be encouraged and tested in clinical practice. © 2016 Published on behalf of the European Society of Cardiology. All rights reserved.


Constantinescu I.,Carol Davila University of Medicine and Pharmacy | Constantinescu I.,Fundeni Clinical Institute | Boscaiu V.,Gheorghe Mihoc Caius Iacob Institute of Mathematical Statistics and Applied Mathematics | Cianga P.,Sf Spiridon Hospital | And 6 more authors.
Immunogenetics | Year: 2016

Knowledge of human leukocyte antigen (HLA) allele frequencies is essential for bone marrow and kidney donor searches. The Romanian Caucasian population is heterogeneous and information on HLA polymorphism has not been well studied. We characterized the HLA genetic profile and allele frequencies of regional populations in Romania. HLA-A, B and DRB1 alleles were examined in 8252 individuals, belonging to the four main regions of Romania. The most common alleles found in the Romanian population are the following: HLA-A*01, A*02, A*03, A*11, A*24; HLA-B*18, B*35, B*44, B*51 and HLA-DRB1*01, DRB1*03, DRB1*07, DRB1*11, DRB1*13, DRB1*15, DRB1*16. More than half of the alleles are non-homogeneously spread in Romania. These results provide a starting point for future analyses of genetic heterogeneity in Romania. © 2015, Springer-Verlag Berlin Heidelberg.


PubMed | Sf Spiridon Hospital, Carol Davila University of Medicine and Pharmacy, Victor Babes University of Medicine and Pharmacy Timisoara, Gheorghe Mihoc Caius Iacob Institute of Mathematical Statistics and Applied Mathematics and Emergency Institute for Cardiovascular Diseases and Transplantation
Type: Journal Article | Journal: Immunogenetics | Year: 2016

Knowledge of human leukocyte antigen (HLA) allele frequencies is essential for bone marrow and kidney donor searches. The Romanian Caucasian population is heterogeneous and information on HLA polymorphism has not been well studied. We characterized the HLA genetic profile and allele frequencies of regional populations in Romania. HLA-A, B and DRB1 alleles were examined in 8252 individuals, belonging to the four main regions of Romania. The most common alleles found in the Romanian population are the following: HLA-A*01, A*02, A*03, A*11, A*24; HLA-B*18, B*35, B*44, B*51 and HLA-DRB1*01, DRB1*03, DRB1*07, DRB1*11, DRB1*13, DRB1*15, DRB1*16. More than half of the alleles are non-homogeneously spread in Romania. These results provide a starting point for future analyses of genetic heterogeneity in Romania.


Hadadi L.,University of Medicine and Pharmacy of Targu Mures | Sus I.,University of Medicine and Pharmacy of Targu Mures | Lakatos E.K.,University of Medicine and Pharmacy of Targu Mures | Serban R.C.,University of Medicine and Pharmacy of Targu Mures | And 3 more authors.
Revista Romana de Medicina de Laborator | Year: 2015

Coronary chronic total occlusion (CTO) is caused by organized thrombi or atherosclerotic plaque progression. The presence of a CTO is an independent predictor of mortality in patients presenting with ST-segment elevation myocardial infarction (STEMI). Platelets have a crucial role in the pathophysiology of atherosclerosis. The aim of this retrospective study was to investigate platelet indices as predictors of CTO in patients with STEMI treated with primary percutaneous coronary intervention (pPCI). A total number of 334 patients admitted for STEMI between January 2011 and December 2013 were included and divided in two groups based on the presence of CTO (48 patients in CTO+ group, 286 patients in CTO- group). Platelet count, mean platelet volume (MPV), platelet distribution width (PDW), platelet-large cell ratio (P-LCR), lymphocyte and neutrophil count determined on admission were analyzed. MPV was larger in patients with CTO compared with patients without CTO (p=0.02), as were PDW (p=0.03) and P-LCR (p=0.01). Platelet-to-lymphocyte ratio (PLT/LYM) was lower in patients with CTO: 105.2 (75.86-159.1) compared to 137 (97-188.1), p<0.01. Receiver-operator characteristic curve analysis identified an area under the curve of 0.61 (95%CI=0.57-0.67, p< 0.01) for PLT/LYM in predicting the presence of a CTO, with a cut-off value at 97.73. Lower values than this were independent predictors of a CTO in multivariate logistic regression analysis, with an Odds Ratio of 2.2 (95%CI=1.15-4.20, p=0.02). Our results support the use of platelet indices and PLT/LYM as predictors of CTO in patients presenting with STEMI. © 2015, University of Medicine and Pharmacy Targu Mures. All rights reserved.


Harpa M.M.,University of Medicine and Pharmacy of Targu Mures | Movileanu I.,University of Medicine and Pharmacy of Targu Mures | Sierad L.N.,Aptus LLC | Cotoi O.S.,University of Medicine and Pharmacy of Targu Mures | And 12 more authors.
Revista Romana de Medicina de Laborator | Year: 2015

Background: We hypothesized that an ideal heart valve replacement would be acellular valve root scaffolds seeded with autologous stem cells. To test this hypothesis, we prepared porcine acellular pulmonary valves, seeded them with autologous adipose derived stem cells (ADSCs) and implanted them in sheep and compared them to acellular valves. Methods: Fresh porcine pulmonary valve roots were decellularized with detergents and enzymes. ADSCs were isolated from subdermal fat and injected within the acellular cusps. Valves were then implanted in an extra-anatomic pulmonary position as RV to PA shunts: Group A (n=6) consisted of acellular valves and Group B (n=6) of autologous stem cell-seeded acellular xenografts. Sheep were followed up for 6 months by echocardiography and histologic analysis was performed on explanted valves. Results: Early evolution was favorable for both groups. All Group A animals had physiologic growth without any signs of heart failure and leaflets were found with preserved structure and mobility, lacking signs of thrombi, inflammation or calcification. Group B sheep however expressed signs of right ventricle failure starting at one month, accompanied by progressive regurgitation and right ventricle dilatation, and the leaflets were found covered with host tissue. No cells were found in any Group A or B explants. Conclusions: Acellular stabilized xenogeneic pulmonary valves are reliable, stable,non-immunogenic, non-thrombogenic and non-calcifying scaffolds with excellent hemodynamics. Seeding these scaffolds with autologous ADSCs was not conducive to tissue regeneration. Studies aimed at understanding these novel observations and further harnessing the potential of stem cells are ongoing. © 2015, University of Medicine and Pharmacy Targu Mures. All rights reserved.


Scridon A.,University of Medicine and Pharmacy of Targu Mures | Serban R.C.,University of Medicine and Pharmacy of Targu Mures | Serban R.C.,Emergency Institute for Cardiovascular Diseases and Transplantation
Therapeutic Drug Monitoring | Year: 2016

Large clinical trials have demonstrated that new oral anticoagulants (NOACs) are at least as efficient as vitamin K antagonists (VKAs) in preventing thromboembolic events, while providing a better safety profile. The relatively stable pharmacokinetics and pharmacodynamics, the reduced reports on food and drug interactions, and the wide therapeutic windows of NOACs appear to provide a more predictable anticoagulant effect than that observed with VKAs, enabling the use of fixed doses without the need for monitoring. However, the safe implementation of NOACs may require additional judgment, and one should not have the erroneous impression that NOACs are free from interactions or that inter-and intra-individual variability is absent with NOACs. In fact, a consensus seems to have been reached concerning the usefulness of "circumstantial" testing in certain clinical scenarios. Recent data also suggest that factors such as intercurrent diseases, drug interactions, and inexplicable variability may occasionally alter the anticoagulant effect of NOACs. Furthermore, the issue of nonadherence, already high in VKA-treated patients, may represent an even greater clinical concern with NOACs, given their short half-lives. This review aims to underline the main arguments that support the need for NOAC monitoring, at least in selected categories of patients. Additionally, an overview of classic coagulation assays and novel laboratory techniques that may provide a tool for NOAC monitoring is also provided. © 2015 Wolters Kluwer Health, Inc.


Sirbu V.I.,University of Medicine and Pharmacy of Targu Mures | Sirbu V.I.,Emergency Institute for Cardiovascular Diseases and Transplantation | Pintilie I.,University of Medicine and Pharmacy of Targu Mures | Opris M.M.,University of Medicine and Pharmacy of Targu Mures | Opris M.M.,Emergency Institute for Cardiovascular Diseases and Transplantation
Revista Romana de Medicina de Laborator | Year: 2014

Venous thromboembolism (VTE) is a multifactorial disease; age, a prior history of deep vein thrombosis, cancer, surgery, obesity, prolonged immobility, pregnancy, oral contraceptive agents, thrombophilia, have been identifed as major risk factors. Thrombophilia is a heritable or acquired prothrombotic state that increases the tendency to venous thromboembolism. The use of anabolic steroids is strongly linked to venous thromboembolism, due to their role in thrombus formation. We present a case of a venous thromboembolism in a 26-year old male who had undergone a testosterone abuse and had a previously undiagnosed genetic thrombophilia, with discussion upon literature regarding the heritable thrombophilia and prothrombotic effects of testosterone.

Loading Emergency Institute for Cardiovascular Diseases and Transplantation collaborators
Loading Emergency Institute for Cardiovascular Diseases and Transplantation collaborators